April 19, 2022
Date: Apr 18, 2022
Duration: 20 Min
Sponsored by WuXi Advanced Therapies
This webcast features: Yiyu Dong, PhD, Associate Director of Viral Vector Process Technology Development (VVPTD), WuXi Advanced Therapies.
Due to their capability for long-term transgene expression, large packaging capacity and ability to transduce postmitotic and quiescent cells, lentiviral vectors have become increasingly popular gene delivery tools for cell and gene therapies in recent years. However, capacity for lentiviral vector manufacture is a major industry bottleneck.
WuXi Advanced Therapies has developed a lentiviral suspension manufacturing platform using OXGENE’s XLenti™ packaging plasmids. Benefits of the XLenti™ suspension platform include:
A high producing single clonal cell line.
Chemically defined culture media.
High producing plasmids, optimized for increased translation efficiency and maximized expression of each cassette.
Simplified and efficient seed train.
Excellent scalability.
Robust upstream and downstream processes.
High viral titer.
This webinar will cover:
Performance data for WuXi Advanced Therapies’ XLenti™ suspension platform.
Solutions for large-scale manufacture of lentiviral vectors.
How to access OXGENE’s optimized XLenti™ packaging plasmids at research, clinical or commercial GMP grades.
Just fill out the form below to watch the recorded webcast now.
You May Also Like
